- Home
- PEO vs CSTL Comparison
PEO vs CSTL Comparison
Compare PEO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEO
- CSTL
- Stock Information
- Founded
- PEO 1929
- CSTL 2007
- Country
- PEO United States
- CSTL United States
- Employees
- PEO N/A
- CSTL N/A
- Industry
- PEO Finance/Investors Services
- CSTL Medical Specialities
- Sector
- PEO Finance
- CSTL Health Care
- Exchange
- PEO Nasdaq
- CSTL Nasdaq
- Market Cap
- PEO 569.6M
- CSTL 561.9M
- IPO Year
- PEO N/A
- CSTL 2019
- Fundamental
- Price
- PEO $21.86
- CSTL $18.82
- Analyst Decision
- PEO
- CSTL Strong Buy
- Analyst Count
- PEO 0
- CSTL 6
- Target Price
- PEO N/A
- CSTL $37.67
- AVG Volume (30 Days)
- PEO 35.4K
- CSTL 425.8K
- Earning Date
- PEO 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- PEO 5.93%
- CSTL N/A
- EPS Growth
- PEO N/A
- CSTL N/A
- EPS
- PEO N/A
- CSTL N/A
- Revenue
- PEO N/A
- CSTL $347,083,000.00
- Revenue This Year
- PEO N/A
- CSTL N/A
- Revenue Next Year
- PEO N/A
- CSTL $1.36
- P/E Ratio
- PEO N/A
- CSTL N/A
- Revenue Growth
- PEO N/A
- CSTL 38.43
- 52 Week Low
- PEO $19.22
- CSTL $15.45
- 52 Week High
- PEO $23.80
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- PEO 55.97
- CSTL 53.48
- Support Level
- PEO $21.83
- CSTL $19.29
- Resistance Level
- PEO $22.34
- CSTL $20.26
- Average True Range (ATR)
- PEO 0.35
- CSTL 0.60
- MACD
- PEO -0.01
- CSTL -0.10
- Stochastic Oscillator
- PEO 56.76
- CSTL 37.64
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.